The Biostatistics &Bioinformatics Core Facility is a shared resource that provides statistical, bioinformatics, and research informatics support to the Case Comprehensive Cancer Center. The Core includes biostatistics, bioinformatics, and research informatics faculty and staff from Case Western Reserve University and Cleveland Clinic.
Specific aims of the Biostatistics &Bioinformatics Core Facility are: 1) To provide statistical, bioinformatics, and research informatics support to Case CCC members in the design, planning, conduct analysis, and reporting of research studies;2) To ensure that Cancer Center studies are designed, conducted and monitored properly by reviewing all protocols and proposals, and participating in ongoing quality control and data and safety monitoring of ongoing studies;3) To provide and coordinate informatics support to the OnCore clinical trials management database and other research databases and serve as a base for research informatics in the Case CCC. The primary focus of the portion of the BBCF funded by the CCSG is to provide support for proposal development, pilot studies, or other NIH-funded peer-reviewed studies. Extensive data analytic efforts are supported by funding of core members on grants or charge-back. The Biostatistics and Bioinformatics Core Facility brings together expertise and intellectual resources in biostatistics, bioinformatics, clinical research informatics, clinical trials, epidemiology, and statistical computing.
The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.
|Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464|
|Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726|
|He, Tian; McColl, Karen; Sakre, Nneha et al. (2018) Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. Mol Oncol 12:2124-2135|
|Roche, Kathryn L; Nukui, Masatoshi; Krishna, Benjamin A et al. (2018) Selective 4-Thiouracil Labeling of RNA Transcripts within Latently Infected Cells after Infection with Human Cytomegalovirus Expressing Functional Uracil Phosphoribosyltransferase. J Virol 92:|
|Bedell, Hillary W; Hermann, John K; Ravikumar, Madhumitha et al. (2018) Targeting CD14 on blood derived cells improves intracortical microelectrode performance. Biomaterials 163:163-173|
|Nagaraj, A B; Wang, Q Q; Joseph, P et al. (2018) Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene 37:403-414|
|Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2018) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev 27:140-143|
|Gu, Xiaorong; Ebrahem, Quteba; Mahfouz, Reda Z et al. (2018) Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest 128:4260-4279|
|Benson, Bryan L; Li, Lucy; Myers, Jay T et al. (2018) Biomimetic post-capillary venule expansions for leukocyte adhesion studies. Sci Rep 8:9328|
|Bosca, Federica; Bielecki, Peter A; Exner, Agata A et al. (2018) Porphyrin-Loaded Pluronic Nanobubbles: A New US-Activated Agent for Future Theranostic Applications. Bioconjug Chem 29:234-240|
Showing the most recent 10 out of 1227 publications